Developing therapeutic vaccines against Alzheimers disease

Expert Review of Vaccines

Volumn 15, Issue 3, 2016, Pages 401-415

  Wisniewski, Thomas ^a   Drummond, Eleanor ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloid ; immunomodulation; immunotherapy; neurodegenerative disease; oligomers; prion disease; tau

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; EPITOPE; TAU PROTEIN; VANUTIDE CRIDIFICAR; AMYLOID PROTEIN; VACCINE;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; BRAIN EDEMA; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; INNATE IMMUNITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VACCINATION; WHITE MATTER LESION; ANIMAL; DISEASE MODEL; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOIDOGENIC PROTEINS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; VACCINES;

EID: 84959076430     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1121815     Document Type: Review

References (140)

1. Association As. Alzheimer Association Report. Alzheimers Demen. 2015; 11: 332-384.
2. Nelson PT, Alafuzoff I, Bigio EH., et al. Correlation of Alzheimers disease neuropathologic changes with cognitive status: a review of the literature. Jnen. 2012; 71: 362-381.
3. Ashe KH, Aguzzi A. Prions, prionoids and pathogenic proteins in Alzheimer disease. Prion. 2013; 7 (1): 55-59.
4. Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011; 70 (4): 532-540.
5. Jaunmuktane Z, Mead S, Ellis M., et al. Evidence for human transmission of amyloid-beta pathology and cerebral amyloid angiopathy. Nature. 2015; 525 (7568): 247-250.
6. Guerreiro R, Hardy J. Genetics of Alzheimers disease. Neurotherapeutics. 2014;11(4):432-437.
7. Wingo TS, Lah JJ, Levey AI., et al. Autosomal recessive causes likely in early-onset Alzheimer disease. Arch Neurol. 2012; 69 (1): 59-64.
8. Karch CM, Cruchaga C, Goate AM. Alzheimers disease genetics: from the bench to the clinic. Neuron. 2014; 83 (1): 11-26.
9. Bertram L, Tanzi RE. The genetics of Alzheimers disease. Prog Mol Biol Transl Sci. 2012; 107: 79-100.
10. Kim DH, Yeo SH, Park JM., et al. Genetic markers for diagnosis and pathogenesis of Alzheimers disease. Gene. 2014;545(2):185-193.
11. Di Marco LY, Marzo A, Munoz-Ruiz M., et al. Modifiable lifestyle factors in dementia: a systematic review of longitudinal observational cohort studies. J Alzheimers Dis. 2014;42(1):119-135.
12. Beydoun MA, Beydoun HA, Gamaldo AA., et al. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC. Public Health. 2014; 14: 643.
13. Karch CM, Goate AM. Alzheimers disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015; 77 (1): 43-51.
14. Kanekiyo T, Xu H, Bu G. ApoE and A in Alzheimers disease: accidental encounters or partners?. Neuron. 2014; 81 (4): 740-754.
15. Potter H, Wisniewski T. Apolipoprotein E: essential catalyst of the Alzheimer amyloid cascade. Int J Alz Dis. 2012; 2012: 489428.
16. Hickman SE, El KJ. TREM2 and the neuroimmunology of Alzheimers disease. Biochem Pharmacol. 2014; 88 (4): 495-498.
17. Boutajangout A, Wisniewski T. The innate immune system in Alzheimers disease. Int J Cell Biol. 2013; 2013: e576383.
18. Tarasoff J, Carare R, Osorio R., et al. Clearance systems in the brain and Alzheimers disease. Nat Neurol Rev. 2015; 11 (8): 457-470.
19. Morrone CD, Liu M, Black SE., et al. Interaction between therapeutic interventions for Alzheimers disease and physiological Aβ clearance mechanisms. Front Aging Neurosci. 2015; 7: 64.
20. Holtzman DM, Mandelkow E, Selkoe DJ. Alzheimer disease in 2020. Cold Spring Harb Perspect Med. 2012; 2 (11):a011585.
21. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics. Science. 2002; 297 (5580): 353-356.
22. Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015; 18 (6): 794-799.
23. Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and wingmen. Nat Neurosci. 2015; 18 (6): 800-806.
24. Solomon B, Koppel R, Frankel D., et al. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA. 1997; 94 (8): 4109-4112.
25. Schenk D, Barbour R, Dunn W., et al. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mice. Nature. 1999; 400: 173-177.
26. Lemere CA. Immunotherapy for Alzheimers disease: hoops and hurdles. Mol Neurodegener. 2013; 8 (1): 36.
27. Sigurdsson EM, Scholtzova H, Mehta P., et al. Immunization with a non-toxic/non-fibrillar amyloid-beta homologous peptide reduces Alzheimers disease associated pathology in transgenic mice. Am J Pathol. 2001; 159: 439-447.
28. Morgan D, Diamond DM, Gottschall PE., et al. Ab peptide vaccination prevents memory loss in an animal model of Alzheimers disease. Nature. 2000; 408: 982-985.
29. Janus C, Pearson J, McLaurin J., et al. Ab peptide immunization reduces behavioural impairment and plaques in a model of Alzheimers disease. Nature. 2000; 408: 979-982.
30. Sigurdsson EM, Knudsen EL, Asuni A., et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimers disease mouse model immunized with amyloid-b derivatives. J Neurosci. 2004; 24: 6277-6282.
31. Asuni A, Boutajangout A, Scholtzova H., et al. Ab derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimers model mice. Eur J Neurosci. 2006; 24: 2530-2542.
32. Bayer AJ, Bullock R, Jones RW., et al. Evaluation of the safety and immunogenicity of synthetic Ab42 (AN1792) in patients with AD. Neurol. 2005; 64: 94-101.
33. Pride M, Seubert P, Grundman M., et al. Progress in the active immunotherapeutic approach to Alzheimers disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis. 2008; 5 (34): 194-196.
34. Wisniewski T, Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimers disease. Brain Pathol. 2005; 15: 72-77.
35. Boche D, Nicoll JA. The role of the immune system in clearance of Ab from the brain. Brain Pathol. 2008; 18 (2): 267-278.
36. Bombois S, Maurage CA, Gompel M., et al. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol. 2007; 64 (4): 583-587.
37. Ferrer I, Boada RM, Sanchez Guerra ML., et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimers disease. Brain Pathol. 2004; 14: 11-20.
38. Masliah E, Hansen L, Adame A., et al. Ab vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurol. 2005; 64: 129-131.
39. Nicoll JA, Wilkinson D, Holmes C., et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2005; 9: 448-452.
40. Nicoll JA, Barton E, Boche D., et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006; 65 (11): 1040-1048.
41. Sadowski M, Wisniewski T. Disease modifying approaches for Alzheimers pathology. Curr Pharmaceutic Des. 2007; 13 (19): 1943-1954.
42. Gilman S, Koller M, Black RS., et al. Clinical effects of Ab immunization (AN1792) in patients with AD in an interrupted trial. Neurol. 2005; 64: 1553-1562.
43. Hock C, Konietzko U, Straffer JR., et al. Antibodies against b-amyloid slow cognitive decline in Alzheimers disease. Neuron. 2003; 38: 547-554.
44. Ryan JM, Grundman M. Anti-amyloid-beta immunotherapy in Alzheimers disease: ACC-001 clinical trials are ongoing. J Alzheimers. 2009; 17 (2): 243.
45. Schneeberger A, Mandler M, Otawa O., et al. Development of AFFITOPE vaccines for Alzheimers disease (AD)-from concept to clinical testing. J Nutr Health Aging. 2009; 13 (3): 264-267.
46. Winblad B, Andreasen N, Minthon L., et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimers disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012; 11 (7): 597-604.
47. Wisniewski T. Active immunotherapy for Alzheimers disease. Lancet Neurol. 2012; 11 (7): 571-572.
48. Wiessner C, Wiederhold KH, Tissot AC., et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011; 31 (25): 9323-9331.
49. Farlow MR, Andreasen N, Riviere ME., et al. Long-term treatment with active Abeta immunotherapy with CAD106 in mild Alzheimers disease. Alzheimers Res Ther. 2015; 7 (1): 23.
50. Graf A, Riviere ME, Caputo A., et al. Active Abeta immunotherapy CAD106 pahse II dose-adjuvant finding study: safety and CNS biomarkers. Alz Dementia. 2014; 10: 274.
51. Muhs A, Hickman DT, Pihlgren M., et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S. 2007; 104 (23): 9810-9815.
52. Hickman DT, Lopez-Deber MP, Ndao DM., et al. Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases. J Biol Chem. 2011; 286 (16): 13966-13976.
53. Saido TC, Iwatsubo T, Mann DM., et al. Dominant and differential deposition of distinct beta-amyloid peptide species, Ab N3(pE), in senile plaques. Neuron. 1995; 14 (2): 457-466.
54. Frost JL, Le KX, Cynis H., et al. Pyroglutamate-3 amyloid-beta deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am J Pathol. 2013; 183 (2): 369-381.
55. DeMattos RB, Lu J, Tang Y., et al. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimers disease mice. Neuron. 2012; 76 (5): 908-920.
56. Bard F, Cannon C, Barbour R., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000; 6 (8): 916-919.
57. DeMattos RB, Bales KR, Cummins DJ., et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimers disease. Proc Natl Acad Sci USA. 2001; 98 (15): 8850-8855.
58. Wisniewski T, Goni F. Immunotherapeutic approaches for Alzheimers disease. Neuron. 2015; 85: 1162-1176.
59. Agadjanyan MG, Petrovsky N, Ghochikyan A. A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimers disease. Alzheimers Dement. 2015;11(10):1246-1259.
60. Sevigny J, Chiao P, Williams L., et al. Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimers disease: interim report of a randomized, double-blind, placebo-controlled, phase 1B study. Alz Dementia. 2015; 11: 4484.
61. Sevigny J, Chiao P, Williams L., et al. Randomized, double-blind, phase 1B study of BIIB037, an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimers disease. Neurodegener Dis. 2015; 15 (suppl 1): 311.
62. Salloway S, Sperling R, Fox NC., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimers disease. N Engl J Med. 2014; 370 (4): 322-333.
63. Doody RS, Thomas RG, Farlow M., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimers disease. N Engl J Med. 2014; 370 (4): 311-321.
64. Bard F, Barbour R, Cannon C., et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimers disease-like neuropathology. Proc Natl Acad Sci U S. 2003; 100 (4): 2023-2028.
65. Salloway S, Sperling R, Gilman S., et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009; 73 (24): 2061-2070.
66. Farlow MR, Brosch JR. Immunotherapy for Alzheimers disease. Neurol Clin. 2013; 31 (3): 869-878.
67. Rinne JO, Brooks DJ, Rossor MN., et al. (11)C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimers disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010; 9 (4): 363-372.
68. Sperling R, Salloway S, Brooks DJ., et al. Amyloid-related imaging abnormalities in patients with Alzheimers disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012; 11 (3): 241-249.
69. Liu E, Schmidt ME, Margolin R., et al. Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology. 2015; 85 (8): 692-700.
70. Dodart JC, Bales KR, Gannon KS., et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimers disease model. Nat Neurosci. 2002; 5 (5): 452-457.
71. DeMattos RB, Bales KR, Cummins DJ., et al. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimers disease. Science. 2002; 295 (5563): 2264-2267.
72. Farlow M, Arnold SE, Van Dyck CH., et al. Safety and biomarker effects of solanezumab in patients with Alzheimers disease. Alzheimers Dement. 2012; 8 (4): 261-271.
73. Lindberg H, Hard T, Lofblom J., et al. A truncated and dimeric format of an Affibody library on bacteria enables FACS-mediated isolation of amyloid-beta aggregation inhibitors with subnanomolar affinity. Biotechnol J. 2015 Jul 14. doi: 10.1002/biot.201500131 [Epub ahead of print].
74. De Genst E, Muyldermans S. Development of a high affinity Affibody-derived protein against amyloid beta-peptide for future Alzheimers disease therapy. Biotechnol J. 2015 Sep 10. doi: 10.1002/biot.201500405 [Epub ahead of print].
75. Siemers ER, Sundell KL, Carlson C., et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimers disease patients. Alzheimers Dement. 2015 Aug 1. pii: S1552-5260(15)02148-2. doi: 10.1016/j.jalz.2015.06.1893 [Epub ahead of print].
76. Bohrmann B, Baumann K, Benz J., et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers. 2012; 28 (1): 49-69.
77. Ostrowitzki S, Deptula D, Thurfjell L., et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2011; 69: 198-207.
78. Adolfsson O, Pihlgren M, Toni N., et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci. 2012; 32 (28): 9677-9689.
79. Morris JC. Mild cognitive impairment is early-stage Alzheimer disease: time to revise diagnostic criteria. Arch Neurol. 2006; 63 (1): 15-16.
80. Puzzo D, Privitera L, Leznik E., et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci. 2008; 28 (53): 14537-14545.
81. Giuffrida ML, Caraci F, Pignataro B., et al. Beta-amyloid monomers are neuroprotective. J Neurosci. 2009; 29 (34): 10582-10587.
82. Soscia SJ, Kirby JE, Washicosky KJ., et al. The Alzheimers disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One. 2010; 5 (3): e9505.
83. Yoshiyama Y, Lee VM, Trojanowski JQ. Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry. 2013; 84 (7): 784-795.
84. Sigurdsson EM. Immunotherapy targeting pathological tau protein in Alzheimers disease and related tauopathies. J Alzheimers. 2008; 15 (2): 157-168.
85. Noble W, Garwood CJ, Hanger DP. Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. Prion. 2009; 3: 2.
86. Kayed R, Jackson GR. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr Opin Immunol. 2009; 21 (3): 359-363.
87. Boutajangout A, Wisniewski T. Tau-based therapeutic approaches for Alzheimers disease-a mini-review. Gerontology. 2014; 60: 381-385.
88. Arriagada PV, Growdon JH, Hedley-Whyte ET., et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimers disease. Neurology. 1992; 42 (3 Pt 1): 631-639.
89. Bancher C, Braak H, Fischer P., et al. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimers and Parkinsons disease patients. Neurosci Lett. 1993; 162 (12): 179-182.
90. Terry RD. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropath Exp Neurol. 1996; 55 (10): 1023-1025.
91. Braak H, Del TK. The pathological process underlying Alzheimers disease in individuals under thirty. Acta Neuropathol. 2011; 121 (2): 171-181.
92. Elobeid A, Soininen H, Alafuzoff I. Hyperphosphorylated tau in young and middle-aged subjects. Acta Neuropathol. 2012; 123 (1): 97-104.
93. Jack CR Jr., Knopman DS, Jagust WJ., et al. Tracking pathophysiological processes in Alzheimers disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12 (2): 207-216.
94. Clavaguera F, Bolmont T, Crowther RA., et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009; 11 (7): 909-913.
95. Clavaguera F, Grueninger F, Tolnay M. Intercellular transfer of tau aggregates and spreading of tau pathology: implications for therapeutic strategies. Neuropharmacology. 2014; 76 Pt A: 9-15.
96. Liu L, Drouet V, Wu JW., et al. Trans-synaptic spread of tau pathology in vivo. PLoS ONE. 2012; 7 (2): e31302.
97. Dujardin S, Lecolle K, Caillierez R., et al. Neuron-to-neuron wild-type tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol Commun. 2014; 2: 14.
98. Asuni AA, Boutajangout A, Quartermain D., et al. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007; 27 (34): 9115-9129.
99. Boutajangout A, Ingadottir J, Davies P., et al. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. 2011; 118 (4): 658-667.
100. Chai X, Wu S, Murray TK., et al. Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J Biol Chem. 2011; 286 (39): 34457-34467.
101. Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimers disease. Trends Mol Med. 2015; 21 (6): 394-402.
102. Kontsekova E, Zilka N, Kovacech B., et al. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimers disease model. Alzheimers Res Ther. 2014; 6 (4): 44.
103. Theunis C, Crespo-Biel N, Gafner V., et al. Efficacy and safety of a liposome-based vaccine against protein tau, assessed in tau.P301L mice that model tauopathy. PLoS One. 2013; 8 (8): e72301.
104. Wisniewski HM, Wegiel J, Wang KC., et al. Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimers disease. Acta Neuropathol. 1992; 84 (2): 117-127.
105. Frackowiak J, Wisniewski HM, Wegiel J., et al. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol. 1992; 84 (3): 225-233.
106. Wisniewski HM, Wegiel J. The role of microglia in amyloid fibril formation. Neuropathol Appl Neurobiol. 1994; 20 (2): 192-194.
107. Yaghmoor F, Noorsaeed A, Alsaggaf S., et al. The role of TREM2 in Alzheimers disease and other neurological disorders. J Alz Dis Parkinsonism. 2014; 4 (5): 160.
108. Zhang B, Gaiteri C, Bodea LG., et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimers disease. Cell. 2013; 153 (3): 707-720.
109. Fiala M, Lin J, Ringman J., et al. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimers disease patients. J Alzheimers. 2005; 7 (3): 221-232.
110. Majumdar A, Cruz D, Asamoah N., et al. Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol Biol Cell. 2007; 18 (4): 1490-1496.
111. Lai AY, McLaurin J. Clearance of amyloid-beta peptides by microglia and macrophages: the issue of what, when and where. Future Neurol. 2012; 7 (2): 165-176.
112. Streit WJ, Xue QS. Human CNS immune senescence and neurodegeneration. Curr Opin Immunol. 2014; 29C: 93-96.
113. Lee DC, Rizer J, Hunt JB., et al. Review: experimental manipulations of microglia in mouse models of Alzheimers pathology: activation reduces amyloid but hastens tau pathology. Neuropathol Appl Neurobiol. 2013; 39 (1): 69-85.
114. Lampron A, Elali A, Rivest S. Innate immunity in the CNS: redefining the relationship between the CNS and its environment. Neuron. 2013; 78 (2): 214-232.
115. Schwartz M, Kipnis J, Rivest S., et al. How do immune cells support and shape the brain in health, disease, and aging?. J Neurosci. 2013; 33 (45): 17587-17596.
116. Tahara K, Kim HD, Jin JJ., et al. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain. 2006; 129 (Pt 11): 3006-3019.
117. Jin JJ, Kim HD, Maxwell JA., et al. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimers disease. J Neuroinflammation. 2008; 5: 23.
118. Reed-Geaghan EG, Savage JC, Hise AG., et al. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci. 2009; 29 (38): 11982-11992.
119. Michaud JP, Halle M, Lampron A., et al. Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimers disease-related pathology. Proc Natl Acad Sci U S. 2013; 110 (5): 1941-1946.
120. Scholtzova H, Kascsak RJ, Bates KA., et al. Induction of Toll-like receptor 9 signaling as a method for ameliorating Alzheimers disease related pathology. J Neurosci. 2009; 29 (6): 1846-1854.
121. Scholtzova H, Chianchiano P, Pan J., et al. Toll-like receptor 9 stimulation for reduction of amyloid b and tau Alzheimers disease related pathology. Acta Neuropathol Commun. 2014; 2: 101.
122. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev. 2009; 61 (3): 195-204.
123. Scholtzova H, Williams L, Nehete P., et al. Innate immunity stimulation via TLR9 in a non-human primate model of sporadic cerebral amyloid angiopathy. Alz Dementia. 2013; 9 (4): 508.
124. C monoclonal antibody infusion as a novel treatment for Ab oligomer cognitive cognitive deficits. BMC Neurosci. 2010; 11: 130.
125. Barry AE, Klyubin I, Mc Donald JM., et al. Alzheimers disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J Neurosci. 2011; 31 (20): 7259-7263.
126. Lee EB, Leng LZ, Zhang B., et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem. 2006; 281 (7): 4292-4299.
127. Moretto N, Bolchi A, Rivetti C., et al. Conformation-sensitive antibodies against Alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J Biol Chem. 2007; 282 (15): 11436-11445.
128. Wisniewski T, Prelli F, Scholtzova H., et al. Immunotherapy targeting abnormal protein conformation. Alz Dementia. 2009; 5 (4, Suppl. 1): 113.
129. Goni F, Prelli F, Ji Y., et al. Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimers disease. PLoS One. 2010; 5 (10): e13391.
130. Goni F, Herline K, Peyser D., et al. Immunomodulation targeting both Ab and tau pathological conformers ameliorates Alzheimers disease pathology in TgSwDI and 3xTg mouse models. J Neuroinflammation. 2013; 10 (1): 150.
131. Vidal R, Frangione B, Rostagno A., et al. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature. 1999; 399 (6738): 776-781.
132. Rostagno A, Tomidokoro Y, Lashley T., et al. Chromosome 13 dementias. Cell Mol Life Sci. 2005; 62 (16): 1814-1825.
133. Herline K, Goni F, Drummond E., et al. Characterization of a novel monoclonal antibody targeting pathological proteins in Alzheimers disease. Jnen. 2015; 74 (6): 625625.
134. Holmes C, Boche D, Wilkinson D., et al. Long term effects of Ab42 immunization in Alzheimers disease: immune response, plaque removal and clinical function. Lancet. 2008; 372: 216-223.
135. Wisniewski T, Goni F. Immunotherapy for Alzheimers disease. Biochem Pharmacol. 2014; 88: 499-507.
136. Crary JF, Trojanowski JQ, Schneider JA., et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014; 128 (6): 755-766.
137. Jellinger KA, Alafuzoff I, Attems J., et al. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol. 2015; 129: 757-762.
138. Jansen WJ, Ossenkoppele R, Visser PJ., et al. Alzheimer disease risk-reply. Jama. 2015; 314 (11): 1177-1178.
139. Walker L, McAleese KE, Thomas AJ., et al. Neuropathologically mixed Alzheimers and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol. 2015; 129 (5): 729-748.
140. Josephs KA, Whitwell JL, Weigand SD., et al. TDP-43 is a key player in the clinical features associated with Alzheimers disease. Acta Neuropathol. 2014;127(6):811-824.